Drugs / SBR759
SBR759
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT00750295 | Feb 2007 → Jan 2008 | chronic kidney disease | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT00704678 | Aug 2008 → Jun 2010 | chronic kidney disease | Novartis Pharmaceuticals | Completed | Met primary |
| Phase 2 | NCT00704483 | Jul 2008 → Aug 2010 | — | Novartis Pharmaceuticals | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | SBR759 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00704678 ↗ |
| Known as | Ferric- starch covalent complex | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095380 ↗ |
| Known as | Seboren | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095380 ↗ |
| Modality | Other / unclassified | “SBR759 is a calcium-free, polymeric, iron(III)-based oral phosphate binder” PMID 21854503 ↗ Nov 2011 |
| Route | Oral | “SBR759 is a calcium-free, polymeric, iron(III)-based oral phosphate binder” PMID 21854503 ↗ Nov 2011 |